Effects of zoledronic acid and exemestane combination therapy on immune function, sex hormones, bone markers, and clinical efficacy in hormone receptor-positive breast cancer patients

The effect of treatment by zoledronic acid combined with exemestane was explored pertaining to the immune function, sex hormones, bone markers, and clinical efficacy in hormone receptor-positive breast cancer patients. Eighty elderly patients with hormone receptor-positive breast cancer were selected as the study subjects who were clinically admitted from December 2016 to December 2021. The study and control groups had 40 cases each and were analyzed according to different treatment methods. The control group received exemestane treatment, while the study group was treated with a combination of zoledronic acid and exemestane. The immune functions, sex hormones, bone markers, clinical efficacy, adverse reactions, life quality scores, serum calcium, and vascular endothelial growth factor for the two groups were analyzed and compared. The cluster of differentiation (CD), E2, P and T levels were lower than those of the control after treatment, and the difference was statistically significant, p < 0.05. Similar effect was observed in β-Cross Laps, serum calcium levels and N-terminal propeptide of type 1precollagen (PINP) levels. Physiological and psychological scores were higher than the control after treatment, and difference was statistically significant, p < 0.05. The incidence of adverse reactions was 20.00% for the study group while 42.50% for control, and the difference was statistically significant, p < 0.05. We conclude that Zoledronic acid combined with exemestane in treating hormone receptor-positive breast cancer patients could improve clinical efficacy, immune function, bone metabolism, quality of life, regulate the sex hormones, and possess drug safety.

Zoledronic acid; Exemestane; Breast cancer; Clinical efficacy; Immunologic function

[1] Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, Budzar AU, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clinical Cancer Research. 2020; 26: 5172–5177.

[2] Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I/II trial of Exemestane, Ribociclib, and Everolimus in women with HR+/HER2− advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clinical Cancer Research. 2021; 27: 4177–4185.

[3] Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. Journal of Clinical Oncology. 2023; 41: 1376–1382.

[4] Makhlin I, McAndrew NP, Wileyto EP, Clark AS, Holmes R, Bottalico LN, et al. Ruxolitinib and exemestane for estrogen receptor-positive, aromatase inhibitor resistant advanced breast cancer. NPJ Breast Cancer. 2022; 8: 122.

[5] Ishikawa T. Differences between zoledronic acid and denosumab for breast cancer treatment. Journal of Bone and Mineral Metabolism. 2023; 41: 301–306.

[6] Sheweita SA, Ammar RG, Sabra SA, Sultan AS. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences. 2021; 16: 112–120.

[7] Sorscher S. Duration and dose of adjuvant zoledronic acid for treatment of early breast cancer. JAMA Oncology. 2022; 8: 171.

[8] Wang Q, Guo G, Ruan Z, Cao H, Guo Y, Bai L, et al. Safety and efficacy of long-term zoledronic acid in advanced breast cancer with bone metastasis in South China. Journal of Oncology. 2020; 2020: 5670601.

[9] Rahimian L, Kalantari Khandani B, Nemati M, Hoseini-Shahrestanak S, Aminizadeh N, Jafarzadeh A. Reduced expression of natural killer cell-related activating receptors by peripheral blood mononuclear cells from patients with breast cancer and their improvement by zoledronic acid. Asian Pacific Journal of Cancer Prevention. 2022; 23: 1661–1669.

[10] Friedl TWP, Janni W, Rack B. Duration and dose of adjuvant zoledronic acid for treatment of early breast cancer—reply. JAMA Oncology. 2022; 8: 171–172.

[11] Kim JW, Lee S, Kim HS, Choi YJ, Yoo J, Park KU, et al. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). Cytokine. 2021; 142: 155487.

[12] Yamada K, Kaise H, Taguchi T, Horiguchi J, Takao S, Suzuki M, et al. Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer. Journal of Bone and Mineral Metabolism. 2022; 40: 998–1006.

[13] Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, et al. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer. 2021; 7: 113.

[14] Buch-Larsen K, Jørgensen NR, Jensen LT, Andersson M, Schwarz P. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study. Scandinavian Journal of Clinical and Laboratory Investigation. 2021; 81: 425–431.

[15] Crocamo S, Binato R, Dos Santos EC, de Paula B, Abdelhay E. Translational results of Zo-NAnTax: a phase II trial of neoadjuvant zoledronic acid in HER2-positive breast cancer. International Journal of Molecular Sciences. 2022; 23: 15515.

[16] Jallouk AP, Paravastu S, Weilbaecher K, Aft RL. Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer. Breast Cancer Research and Treatment. 2021; 187: 135–144.

[17] Huang X, Liu Y, Lin S, Wang H, Deng Y, Rao X, et al. Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis. International Journal for Quality in Health Care. 2023; 35: mzad016.

[18] Liu M, Qian S, Wu J, Xiao J, Zeng X. The effects of neoadjuvant zoledronic acid in breast cancer patients: a meta-analysis of randomized controlled trials. Asian Journal of Surgery. 2023; 46: 4124–4130.

[19] Matsuura K, Saeki T, Takahashi T, Torigoe T, Watarai K, Osaki A, et al. Bilateral femoral head osteonecrosis in a patient with metastatic breast cancer receiving long-term zoledronic acid treatment: a case report. Molecular and Clinical Oncology. 2021; 15: 166.

[20] Chacko G, Kota S, Kumar S, Ohri N, Omene C, Ganesan S, et al. Uveitis, is a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer. Anti-Cancer Drugs. 2023; 34: 592–594.